{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Holscher C"],"funding":["Deutsches Zentrum für Infektionsforschung","Innovative Medicines Initiative","Deutsche Forschungsgemeinschaft","Center for Molecular Medicine Cologne, University of Cologne"],"pagination":["13629"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7423948"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(1)"],"pubmed_abstract":["Host-modulating therapies have become an important focus in the development of novel concepts for improved management of tuberculosis (TB). Previous in vitro studies revealed that the p38 MAP kinase signaling pathway coordinates several inflammatory and stress responses in Mycobacterium tuberculosis (Mtb)-infected host cells. Here we extend these findings and show that in vivo treatment of Mtb-infected C57BL/6 mice with doramapimod, a p38 MAP-kinase inhibitor, results in reduced inflammation, granuloma formation and lung pathology. Moreover, doramapimod, together with standard antibiotic treatment, significantly reduced lung and spleen mycobacterial loads compared to antibiotic treatment alone. Our in vivo data suggest the opportunity to repurpose p38 MAPK inhibitors for adjunct host direc"],"journal":["Scientific reports"],"pubmed_title":["Chemical p38 MAP kinase inhibition constrains tissue inflammation and improves antibiotic activity in Mycobacterium tuberculosis-infected mice."],"pmcid":["PMC7423948"],"funding_grant_id":["853989","TTU 02.905","TTU 02.806","ZMMK-CAP8","RY 159"],"pubmed_authors":["Rybniker J","Muller AL","Holscher A","Schafer SC","Grab J","Holscher C"],"additional_accession":[]},"is_claimable":false,"name":"Chemical p38 MAP kinase inhibition constrains tissue inflammation and improves antibiotic activity in Mycobacterium tuberculosis-infected mice.","description":"Host-modulating therapies have become an important focus in the development of novel concepts for improved management of tuberculosis (TB). Previous in vitro studies revealed that the p38 MAP kinase signaling pathway coordinates several inflammatory and stress responses in Mycobacterium tuberculosis (Mtb)-infected host cells. Here we extend these findings and show that in vivo treatment of Mtb-infected C57BL/6 mice with doramapimod, a p38 MAP-kinase inhibitor, results in reduced inflammation, granuloma formation and lung pathology. Moreover, doramapimod, together with standard antibiotic treatment, significantly reduced lung and spleen mycobacterial loads compared to antibiotic treatment alone. Our in vivo data suggest the opportunity to repurpose p38 MAPK inhibitors for adjunct host direc","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Aug","modification":"2025-04-19T23:37:47.688Z","creation":"2025-04-19T23:37:47.688Z"},"accession":"S-EPMC7423948","cross_references":{"pubmed":["32788581"],"doi":["10.1038/s41598-020-70184-x"]}}